ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: ELND005 (scyllo-inositol)
- Registration Number
- NCT00934050
- Lead Sponsor
- OPKO Health, Inc.
- Brief Summary
The purpose of this study is to evaluate the long-term safety and tolerability of ELND005 beyond the 18 months of treatment in original randomized and blinded clinical trail ELND005-AD201.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 103
- This study is open only to subjects who have completed the week 78 visit in Study ELND005-AD201 while taking their assigned dose of study drug medication.
- Subject has no new medical contraindications to continued participation in the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description ELND005 ELND005 (scyllo-inositol) -
- Primary Outcome Measures
Name Time Method Treatment Emergent Adverse Events (TEAEs) 12 months Safety and Tolerability was assessed by the incidence of Treatment Emergent Adverse Events (TEAEs)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (38)
Innovative Clinical Concepts
🇺🇸Paducah, Kentucky, United States
Raleigh Neurology Associates
🇺🇸Raleigh, North Carolina, United States
Premiere Research Institute
🇺🇸West Palm Beach, Florida, United States
Emory University, Dept. of Neurology
🇺🇸Atlanta, Georgia, United States
University of Pittsburgh Alzheimer Disease Research Clinic
🇺🇸Pittsburgh, Pennsylvania, United States
Brain Matters Research
🇺🇸Delray Beach, Florida, United States
Neurological Associates of Albany, PC
🇺🇸Albany, New York, United States
Banner Alzheimer's Institute
🇺🇸Phoenix, Arizona, United States
Department of Neurology - Indiana University Medical Center
🇺🇸Indianapolis, Indiana, United States
Summit Research Newtwork, Inc.
🇺🇸Portland, Oregon, United States
University of Kansas Medical Center, Department of Neurology
🇺🇸Kansas City, Kansas, United States
Sun Health Research Institute
🇺🇸Sun City, Arizona, United States
University of Arizona, Health Sciences Center, Dept. of Neurology
🇺🇸Tucson, Arizona, United States
Collaborative NeuroScience Network, Inc.
🇺🇸Garden Grove, California, United States
Sunrise Clinical Research, Inc
🇺🇸Hollywood, Florida, United States
Roskamp Institute
🇺🇸Sarasota, Florida, United States
Dekalb Neurology Associates, LLC
🇺🇸Decatur, Georgia, United States
Memory Enhancement Center of America, Inc.
🇺🇸Eatontown, New Jersey, United States
Albuquerque Neuroscience, Inc.
🇺🇸Albuquerque, New Mexico, United States
Global Medical Institutes
🇺🇸Princeton, New Jersey, United States
Columbia University Sergievsky Center
🇺🇸New York, New York, United States
AD-CARE, Monroe Community Hospital
🇺🇸Rochester, New York, United States
Neurology & Neuroscience Center of Ohio
🇺🇸Toledo, Ohio, United States
Medford Neurological and Spine Clinic
🇺🇸Medford, Oregon, United States
The Clinical Trial Center, LLC
🇺🇸Jenkintown, Pennsylvania, United States
Alliance for Neuro Research, LLC dba Absher Neurology, PA
🇺🇸Greenville, South Carolina, United States
Butler Hospital, Memory and Aging Center
🇺🇸Providence, Rhode Island, United States
Clinical Neuroscience Research Associates, Inc-The Memory Clinic
🇺🇸Bennington, Vermont, United States
University of British Columbia Hospital, Division of Neurology
🇨🇦Vancouver, British Columbia, Canada
Parkwood Hospital
🇨🇦London, Ontario, Canada
Glenrose Rehabilitation Hospital
🇨🇦Edmonton, Alberta, Canada
Whitby Mental Health Memory Clinic
🇨🇦Toronto, Ontario, Canada
Sisters of Charity of Ottawa Health Service
🇨🇦Ottawa, Ontario, Canada
Kawartha Regional Memory Clinic
🇨🇦Peterborough, Ontario, Canada
Gerontion Research, Inc.
🇨🇦Toronto, Ontario, Canada
Recherche Clinique de Neurologie (Hospital Maisonneuve Rosemont)
🇨🇦Montreal, Quebec, Canada
Margolin Brain Institute
🇺🇸Fresno, California, United States
Yale University School of Medicine, Alzheimer's Disease Research Unit
🇺🇸New Haven, Connecticut, United States